Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA for Prevention of Recurrence of Clostridioides Difficile Colitis
NCT06884748Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ursodeoxycholic acid in Clostridioides difficile infection (CDI), sponsored by Medical College of Wisconsin. Primary endpoint: Lack of recurrent C. difficile recurrence at 3 months. Started Jun 2026; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06884748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884748.